Antiretroviral-based HIV-1 prevention: Antiretroviral treatment and pre-exposure prophylaxis

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1483-1493

  Celum, Connie ^a   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; PLACEBO; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MONITORING; NONHUMAN; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; VIROLOGY; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; PREMEDICATION; PUBLIC HEALTH;

EID: 84871855684     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2492     Document Type: Review

References (74)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-929. (Pubitemid 30177052)
2. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE 2010; 5:e12598.
3. Baeten J, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3: 77ra29.
4. Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, Loutfy MR. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naive HIV-infected individuals initiating combination antiretroviral therapy. HIV Clin Trials 2010; 11: 340-350.
5. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21: 501-507.
6. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997; 71: 6271-6275. (Pubitemid 27304979)
7. Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 2008; 22: 1677-1679.
8. Cu-Uvin S, Caliendo AM. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2011; 25:880-881.
9. Vernazza PL. Genital shedding of HIV-1 despite successful antiretroviral therapy. Lancet 2001; 358: 1564. (Pubitemid 33101898)
10. Mofenson LM. Can perinatal HIV infection be eliminated in the United States? JAMA 1999; 282: 577-579. (Pubitemid 29380296)
11. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146: 591-601. (Pubitemid 351650540)
12. Montaner JS, Hogg R, Wood E, et al . The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368: 531-536. (Pubitemid 44142776)
13. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
14. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-2098.
15. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
16. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
17. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'Test and Treat' in hyperendemic settings. AIDS 2010; 24:729-735.
18. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010; 51: 725-731.
19. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056.
20. HIV Prevention Trials Network. HPTN 065: TLC-Plus, a study to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in the United States. (Accessed 10 April 2012.) Available from http://www.hptn.org/research-studies/hptn065.asp
21. El-Sadr W. ART for prevention: the science and the art. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 18.
22. El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 2011; 25: 2295-2299.
23. World Health Organization. Guidance on couples HIV testing and counselling and antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. Geneva: World Health Organization 2012.
24. Connor EM, Sperling RS, Gelber R, et al . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
25. Chasela CS, Hudgens MG, Jamieson DJ, et al . Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-2281.
26. Mofenson LM. Protecting the next generation - eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362:2316-2318.
27. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5: e28.
28. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.
29. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007; 21: 1899-1907. (Pubitemid 47329766)
30. Patterson KB, Prince HA, Kraft E, et al . Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re114.
31. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-2739. (Pubitemid 32906664)
32. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83:10358-10365.
33. Subbarao S, Otten RA, Ramos A, et al . Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006; 194: 904-911. (Pubitemid 44454075)
34. Cong ME, Youngpairoj AS, Zheng Q, et al . Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol 2011; 85: 7933-7936.
35. Veazey R, Ketas T, Dufour J, Klasse P, Moore J. Protection of rhesus macaques from vaginal infection by maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 84LB.
36. Dobard C, Sharma S, Parikh U, et al . High protection against vaginal infection in macaques by PEP with gel containing RAL. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 30.
37. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
38. Karim SS, Kashuba AD, Werner L, Abdool Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378: 279-281.
39. Andrei G, Lisco A, Vanpouille C, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011; 10:379-389.
40. Hendrix C, Minnis A, Guddera V, et al . MTN-001: a Phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th Conference on Retroviruses and Opportunistic Infections . 27 February-2 March 2011, Boston, MA, USA. Abstract 35LB.
41. Grant RM, Lama JR, Anderson PL, et al . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
42. Anderson P, Lama J, Buchbinder S, et al . Interpreting detection rates of intracellular FTC-TP and TFV-DP: the iPrEx trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI). 27 February-2 March 2011, Boston, MA, USA. Abstract 96LB.
43. Liegler T, Abdel-Mohsen M, Atchison R, et al. Drug resistance and minor drug resistant variants in iPrEx. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 97LB.
44. Anderson P, Liu A, Buchbinder S, et al. Intracellular tenofovir-DP concentrations associated with PrEP efficacy in MSM from iPrEx. 19th Conference on Retroviruses and Opportunistic Infections (CROI). 5-8 March 2012, Seattle, WA, USA. Abstract 31LB.
45. Liu A, Vittinghoff E, Irby R, et al . BMD loss in HIV- men participating in a TDF PrEP clinical trial in San Francisco. 18th Conference on Retroviruses and Opportunistic Infections . 27 February-2 March 2011, Boston, MA, USA. Abstract 93.
46. Family Health International (FHI). VOICE HIV prevention trial continues, but researchers suspend oral tenofovir arm because of futility. (Updated 28 September 2011. Accessed 28 September 2011.) Available from http://www.fhi360. org/en/AboutFHI/Media/Releases/res-VOICE.htm
47. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
48. Anderson P, Meditz A, Zheng J-H, et al . Cellular pharmacology of tenofovir and emtricitabine in blood, rectal, and cervical cells from HIV- volunteers. 19th Conference on Retroviruses and Opportunistic Infections . 5-8 March 2012, Seattle, WA, USA. Abstract 587.
49. Thigpen MC, Kebaabetswe PM, Paxton LA, et al . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-434.
50. Mujugira A, Baeten JM, Donnell D, et al . Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS ONE 2011; 6: e25828.
51. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med 2012; 367: 399-410.
52. Bangsberg D, Haberer J, Psaros C, et al . High adherence and high effectiveness observed in HIV discordant couples: Partners PrEP Study, adherence monitoring and counseling substudy. 19th Conference on Retroviruses and Opportunistic Infections . 5-8 March 2012, Seattle, WA, USA. Abstract 1067.
53. Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. 19th Conference on Retroviruses and Opportunistic Infections . 5-8 March 2012, Seattle, WA, USA. Abstract 30.
54. National Institute of Allergy and Infectious Diseases (NIAID). NIH modifies 'VOICE' HIV prevention study in women. (Updated 28 September 2011. Accessed 28 September 2011.) Available from http://www.nih.gov/news/health/ sep2011/niaid-28.htm.
55. National Institute of Allergy and Infectious Diseases (NIAID). NIH discontinues tenofovir vaginal gel in 'Voice' HIV prevention study. (Updated 25 November 2011. Accessed 27 January 2011.) Available from http://www.nih.gov/ news/health/nov2011/niaid-25.htm.
56. Martin M, Vanichseni S, Suntharasamai P, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok tenofovir study, Thailand. PLoS ONE 2011; 6: e25127.
57. FACTS Consortium. Facts 001 study design. (Accessed 11 April 2012.) Available from http://www.facts-consortium.co.za/?page-id=227
58. HIV Prevention Trials Network. HPTN 067: The ADAPT Study, a Phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). (Accessed 10 April 2012.) Available from http://www.hptn.org/research-studies/hptn067.asp
59. The IPERGAY Study. (Accessed 11 April 2012.) Available from http://www.ipergay.fr/
60. Grabbe KL, Bunnell R. Reframing HIV prevention in sub-Saharan Africa using couple-centered approaches. JAMA 2010; 304:346-347.
61. Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, Mills EJ. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 770-777.
62. Coburn BJ, Gerberry DJ, Blower S. Quantification of the role of discordant couples in driving incidence of HIV in sub-Saharan Africa. Lancet Infect Dis 2011; 11: 263-264.
63. Chemaitelly H, Cremin I, Shelton J, Hallett TB, Abu-Raddad LJ. Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect 2012; 88:51-57.
64. Dunkle KL, Stephenson R, Karita E, et al . New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008; 371: 2183-2191. (Pubitemid 351885039)
65. Ware NC, Wyatt M, Haberer J, et al. What's love got to do with it? A theory of adherence to once-daily oral pre-exposure prophylaxis (PrEP) for HIV prevention derived from qualitative data among HIV serodiscordant couples. J Acquir Immune Defic Syndr 2012; 59: 463-468.
66. Haberer J, Baeten J, Celum C, et al . Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP Study. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 488.
67. Curran K, Baeten J, Coates T, Kurth A, Mugo N, Celum C. HIV-1 Prevention for HIV-1 Serodiscordant Couples. Curr HIV/AIDS Rep 2012; 9: 160-170.
68. Hallett TB, Baeten J, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8: e1001123.
69. Walensky R. Cost-effectiveness in HIV care: understanding value in a world of limited resources. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 74.
70. Hallett TB, Baeten JM, Heffron R, et al . Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8: e1001123.
71. Hurt CB, Eron JJ, Jr., Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011; 53: 1265-1270.
72. Romano J, Variano B, Coplan P, et al . Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25: 483-488.
73. UNAIDS. UNAIDS data tables: 2011. (Accessed 10 April 2012.) Available from http://www.unaids.org/en/media/ unaids/contentassets/documents/ unaidspublication/2011/JC2225-UNAIDS-datatables-en.pdf
74. Cates W. HPTN 052 and the future of HIV treatment and prevention. Lancet 2011; 378:224-225.